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Summary
 
During gram-negative bacterial infections, lipopolysaccharide (LPS) stimulates primed mac-
rophages (M
 
f
 
) to release inflammatory mediators such as tumor necrosis factor (TNF)-
 
a
 
,
which can cause hypotension, organ failure, and often death. Several different receptors on M
 
f
 
have been shown to bind LPS, including the type A scavenger receptor (SR-A). This receptor
is able to bind a broad range of polyanionic ligands such as modified lipoproteins and lipotei-
choic acid of gram-positive bacteria, which suggests that SR-A plays a role in host defense. In
this study, we used mice lacking the SR-A (SRKO) to investigate the role of SR-A in acquired
immunity using a viable bacillus Calmette Guérin (BCG) infection model. We show that acti-
vated M
 
f
 
 express SR-A and that this molecule is functional in assays of adhesion and endocytic
uptake. After BCG infection, SRKO mice are able to recruit M
 
f
 
 to sites of granuloma forma-
tion where they become activated and restrict BCG replication. However, infected mice lack-
ing the SR-A are more susceptible to endotoxic shock and produce more TNF-
 
a
 
 and interleu-
kin-6 in response to LPS. In addition, we show that an antibody which blocks TNF-
 
a
 
 activity
reduces LPS-induced mortality in these mice. Thus SR-A, expressed by activated M
 
f
 
, plays a
protective role in host defense by scavenging LPS as well as by reducing the release by activated
M
 
f
 
 of proinflammatory cytokines. Modulation of SR-A may provide a novel therapeutic ap-
proach to control endotoxic shock.
 
T
 
he macrophage (M
 
f
 
)
 
1
 
 scavenger receptor type A (SR-
A) is a trimeric integral membrane glycoprotein which
exists in two forms, type I and II, generated by alternative
splicing of a single gene product (1–4). This family of SRs
has recently been extended through the discovery of sev-
eral additional SR genes and now includes at least three in-
dependent SR classes (5). SRs are defined according to
their ability to bind and mediate uptake of modified low
density lipoproteins (LDL), such as acetylated (Ac) LDL. The
recent detection of SR-A in atheromatous plaques, and its
ability to mediate uptake of modified LDL by arterial wall
M
 
f
 
, has implicated the molecule in the pathogenesis of
atherosclerosis (6–8).
The range of ligands recognized by SR-A is wide, in-
cluding LPS of gram-negative and lipoteichoic acid of
gram-positive bacteria (9, 10). SR-A types I and II exhibit
similar binding properties, specifically binding a large selec-
tion of polyanionic ligands with high affinity. This broad
ligand specificity has suggested that SR-A may play a role
in a wide range of M
 
f
 
-associated physiological and patho-
physiological processes (11–13). For example, Janeway has
suggested that such receptors may have arisen early in the
evolution of host defense systems and could enable self/
nonself discrimination (14). SR-A is expressed on a wide
range of tissue M
 
f
 
 and also on the sinusoidal endothelium
of the liver (15). This tissue distribution is consistent with a
pattern recognition function for SR-A and also suggests
that it may play a role in host defense by recognizing and
mediating the clearance of pathogens (16).
Recently the repertoire of SR-A functions has been ex-
tended. Work in our laboratory, using a monoclonal anti-
body (2F8) which recognizes the mouse type I and II SR-A,
 
1
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has established that SR-A mediates a component of adhe-
sion of M
 
f
 
 in vitro (17). SR-A might therefore function as
an adhesion molecule in vivo and act to retain M
 
f
 
 within
ligand-rich tissues. Support for this theory has come from
observations, using physiological ligands, that SR-A can
mediate in vitro adhesion of rodent microglia and human
monocytes to 
 
b
 
-amyloid fibril–coated surfaces, implicating
SR-A in the pathogenesis of Alzheimers disease (18). An
additional role for SR-A may be as a receptor used in the
phagocytosis of apoptotic cells in the thymus (19).
This study was designed to further our understanding of
the role of SR-A in host defense. In a model of cell-medi-
ated immunity, we identify activated M
 
f
 
 and examine
whether SR-A is required for M
 
f
 
 recruitment to sites of
granuloma formation. Previous studies have shown that
M
 
f
 
 can bind, internalize, and partially break down LPS,
lipid A, and its bioactive precursor lipid IVa (9). This bind-
ing and subsequent metabolism to a less active form by
M
 
f
 
-like RAW 264.7 cells is mediated by the SR-A. SR-A
ligands greatly inhibit uptake of lipid IVa in mice (9). Taken
together, these observations suggested that SR-A may have
a role in the uptake and degradation of endotoxin in ani-
mals. Using wild-type and SR-A–deficient (SRKO) mice,
we investigate an in vivo role for SR-A in the body’s re-
sponse to LPS. These results provide the first evidence that
SR-A acts to prevent the development of endotoxic shock.
 
Materials and Methods
 
Animals.
 
Mice deficient in type I and II SR-A were pro-
duced by disruption of exon 4 of the SR-A gene that codes for
the 
 
a
 
-helical coiled coil domain, which is essential for the forma-
tion of functional trimeric receptors (4). These mice were bred
onto a 129/ICR background and are described here as SRKO.
Wild-type 129 mice were cross-bred on to an identical 129/ICR
background and are described here as 129 mice. Brother–sister
matings were used to generate homozygous SRKO and 129 mice
on an identical genetic background. Mice used in these experi-
ments were housed at the Dunn School of Pathology and were
used between 6 and 10 wk of age.
 
Media and Reagents.
 
RPMI 1640 (GIBCO BRL, Paisley, UK)
was supplemented with 10% heat-inactivated fetal bovine serum
(GIBCO BRL), 10 mM Hepes, 2 mM glutamine, 100 U/ml peni-
cillin, and 100 
 
m
 
g/ml streptomycin (R10). All chemicals were ob-
tained from Sigma Chemical Co. (St. Louis, MO) unless otherwise
specified.
 
Antibodies.
 
The following rat anti–mouse mAbs were prepared
in our laboratory and were used as diluted hybridoma superna-
tants unless specified; F4/80, specific for an M
 
f
 
 plasma mem-
brane antigen (20, 21); FA11, which recognizes macrosialin (22,
23); 2F8, which recognizes class I and II SR-A (24); and TIB
120, which recognizes class II MHC (25). The hamster mAb
TN3 19.12 used in vivo was a gift of Dr. R. Schreiber (Washing-
ton University, St. Louis, MO) and was used at 250 
 
m
 
g/mouse.
The IgG2b isotype-matched controls, CAMPATH (CP)-1G (rat
anti–human) and anti–Thy-1 (rat anti–canine) were a gift of Dr. S.
Cobbold (University of Oxford, Oxford, UK; reference 26).
 
Microorganisms and Determination of Bacillus Calmette Guérin
(BCG) CFU.
 
Live BCG (Pasteur strain) was provided by Dr.
G. Milon (Pasteur Institut, Paris, France). BCG stocks were
stored at 
 
2
 
70
 
8
 
C, thawed, and sonicated immediately before use.
Mice were inoculated with 
 
z
 
10
 
7
 
 CFU in 0.2 ml of PBS by intra-
peritoneal injection. Organs were removed from the mice at var-
ious time points after inoculation with BCG. A sample of the or-
gan (0.2 g) was homogenized in 5 ml of sterile PBS containing
0.02% BSA and 0.05% Tween 20. 10-fold serial dilutions of the
homogenate were prepared and 25 
 
m
 
l was plated onto a quadrant
of a plate containing Middlebrook 7A10 agar with OADC enrich-
ment (Difco, Detroit, MI). Plates were incubated at 37
 
8
 
C and
colonies of BCG were counted 10–14 d later.
Inactivated 
 
Corynebacterium parvum (Propionibacterium acnes)
 
whole cells were purchased from RIBI Immunochemical Re-
search Inc. (Hamilton, MT). Organisms were washed in nonpy-
rogenic saline twice, resuspended in PBS, and sonicated before
use. Mice were inoculated with 500 
 
m
 
g in 0.2 ml of PBS by in-
traperitoneal injection.
 
Flow Cytometry.
 
SRKO and 129 mice were injected intra-
peritoneally with 10
 
7
 
 CFU of BCG. 5 d later, peritoneal cells were
harvested, resuspended in R10, and plated onto tissue culture plas-
tic (TCP) dishes. 5 h later nonadherent cells were removed by re-
peated washing with PBS. Lidocaine (4 mg/ml) and EDTA (5 mM)
in PBS were used to lift the M
 
f
 
 from the plate. The cells were
fixed on ice for 40 min using 4% paraformaldehyde/250 mM Hepes
in PBS. The cells were then permeabilized for 30 min at 4
 
8
 
C us-
ing saponin (0.1%) in PBS. Cells were resuspended in FACS
 
Ò
 
buffer (0.1% saponin, 0.1% BSA, 1% normal mouse serum, and
10 mM sodium azide) and incubated with primary antibodies
(e.g., 10 
 
m
 
g/ml purified 2F8 or CP) for 1 h, washed three times,
and incubated for 1 h with FITC-conjugated mouse anti–rat sec-
ond Ab (Jackson ImmunoResearch Labs., West Grove, PA) at a
1:500 dilution. The cells were washed and analyzed on a FACS-
can
 
Ò
 
 using Cellquest software.
 
Adhesion Assays.
 
BCG peritoneal cells were harvested as de-
scribed for flow cytometry. Cells were plated in R10 at 3 
 
3
 
 10
 
5
 
M
 
f
 
/well in a 96-well plate in the presence of various antibodies
and/or EDTA. Plates were incubated at 4
 
8
 
C for 30 min, then at
37
 
8
 
C for 90 min before washing to remove nonadherent cells.
Adherent cells were fixed in methanol and stained with 40% Gi-
emsa for 1 h. The level of adhesion was quantified by solubilizing
the dye in methanol and reading the OD at 450 nm. Adhesion
(mean 
 
6
 
 SD) is represented as the percentage of that obtained in
medium alone, and is the result of quadruplicate well assays.
 
Endocytic Uptake of DiIAcLDL. (Biogenesis, Bournemouth, UK).
 
SRKO and 129 mice were injected intraperitoneally with 10
 
7
 
CFU of BCG. 7 d later, peritoneal cells were harvested and resus-
pended in R10. Cells were plated at 3 
 
3
 
 10
 
5
 
 M
 
f
 
/well of a 96-well
plate and cultured overnight. Nonadherent cells were removed
by washing with PBS. Medium (R10) was added containing either
the 2F8 or isotype control (CP) antibodies, and the plate was
placed on ice for 30 min. DiIAcLDL was added to each well and
the plate was incubated at 37
 
8
 
C for 5 h. The cells were washed,
resuspended using 5 mM EDTA/4 mg/ml lidocaine, and the dye
was solubilized with Butan-1-ol. Fluorescence was read on a Flu-
oroskan II plate reader (Titertek; ICN, Costa Mesa, CA). Uptake
of DiIAcLDL is expressed as units of fluorescence (mean 
 
6
 
 SD)
of four replicate wells.
 
Immunohistochemistry.
 
At day 25 of BCG infection, livers
were harvested from 129 and SRKO mice, frozen in OCT com-
pound (BDH-Merck, Dorset, UK), and cooled in isopentane over
dry ice. Frozen sections were cut at 5 
 
m
 
m and fixed for 10 min in
2% paraformaldehyde before staining. Sections were washed in
0.1% Triton X-100 in PBS . Endogenous peroxidase activity was
quenched by incubation of sections with 10
 
2
 
2
 
 M glucose, 10
 
2
 
3
 
 M 
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sodium azide, and 40 U glucose oxidase in 100 ml PBS for 15
min at 37
 
8
 
C. Avidin/biotin blocking agents (Vector Labs., Peter-
borough, UK) were used according to the supplier’s recommen-
dation. Fetal bovine serum (10%) and normal rabbit serum (5%) were
then used to block irrelevant binding sites and sections were in-
cubated for 60 min in hybridoma supernatant or isotype-matched
control Ab. Sections were washed, affinity-purified, and then bio-
tinylated second Ab was added at 1% for 30 min. The sections
were washed and avidin-biotin-peroxidase complex (ABC elite;
Vector Labs.) was used for 30 min according to the supplier’s rec-
ommendation. The presence of antigen was revealed by incu-
bation with 0.5 mg/ml diaminobenzidine (Polysciences Inc.,
Northampton, UK) and 0.024% hydrogen peroxide in 10 mM
PBS imidazole. Sections were counterstained with cresyl violet
acetate and mounted in DPX (BDH-Merck).
 
Assessment of Biological Response to LPS.
 
Mice (age-matched
wild-type and SRKO) were injected intraperitoneally with 10
 
7
 
CFU of BCG. At 14 d after infection, mice were injected with
various doses of LPS from 
 
Salmonella typhimurium
 
 (Westphal
strain; Difco) in nonpyrogenic saline intraperitoneally. To block
the activity of TNF-
 
a
 
, 250 
 
m
 
g of TN3 19.12 mAb was given to
the mice 10 h before administration of the LPS. The condition of
the mice was monitored regularly over 5 d and those suffering
significant morbidity were killed.
 
Cytokine Assays.
 
SRKO and 129 mice were injected intra-
peritoneally with 
 
z
 
10
 
7
 
 CFU of BCG. At 14 d after infection,
mice were injected with 10 
 
m
 
g of LPS intraperitoneally. The
concentration of TNF-
 
a
 
 and IL-6 in serum at various time points
after injection was determined using capture ELISAs. In brief, for
the TNF-
 
a
 
 assay, 50 
 
m
 
l of TN3 19.12 mAb (4 
 
m
 
g/ml) in carbon-
ate buffer (pH 9.6) were added per well of a 96-well plate (Steri-
lin, Stone, UK) and left at 4
 
8
 
C overnight. Plates were washed
twice with PBS/0.05% Tween 20 and twice with PBS alone, and
then samples of the sera (1:10 dilution in R10) were added along
with a dilution series of recombinant murine TNF-
 
a
 
 (Serotec,
Kidlington, Oxford, UK). Plates were incubated overnight at
4
 
8
 
C, washed as above, and then 100 
 
m
 
l/well of rabbit anti–
murine TNF-
 
a
 
 (Serotec; 1:1000 in PBS) was added and left at
room temperature for 90 min. Plates were washed as above, don-
key  anti–rabbit horseradish peroxidase (Chemikon International,
Inc., Temecula, CA) at 1:1,000 in PBS/Tween (0.05%)/BSA
(0.1%) was added and incubated at 20
 
8
 
C for 1 h. Plates were
washed and then 100 
 
m
 
l of reaction mix was added as recom-
mended by supplier. The reaction was stopped by the addition of
50 
 
m
 
l of 3 M sulfuric acid and plates were read at 492 nM. A sim-
ilar protocol was adopted for measurement of IL-6 using appro-
priate antibodies (PharMingen, San Diego, CA).
 
Statistics.
 
Parametric data for cytokine assays and DiIAcLDL
endocytic uptake were compared using Student’s 
 
t
 
 test with the
Welch modification to compensate for different levels of variance
for data sets. Survival data were compared using a likelihood ratio
test (27).
 
Results
 
Expression and Function of SR-A on BCG-activated M
 
f
 
.
 
4–6 d after intraperitoneal injection of BCG, a mixed leu-
kocyte population which is rich in M
 
f
 
 can be harvested
(28). These M
 
f
 
 have undergone a process of activation me-
diated by IFN-
 
g
 
, resulting in changes in both secreted
products and cell surface receptor expression. Using immu-
nostaining with FA11, a pan-M
 
f marker which recognizes
the intracellular protein macrosialin, the Mf in the perito-
neal population were identified (Fig. 1, c and d; reference 22).
Similar numbers of peritoneal Mf were harvested from
wild-type and SRKO mice (z2 3 107 Mf/mouse). Using
an electronic gate to select FA11 positive cells, BCG-acti-
vated Mf from the wild-type mice were shown to express
SR-A, whereas BCG-activated peritoneal Mf from the
SRKO mouse lacked the SR-A (Fig. 1, a and b). The TIB
120 mAb was used to demonstrate that despite lacking SR-A,
BCG-primed Mf from SRKO mice were activated and
expressed MHC class II (Fig. 1, e and f). Supporting evi-
dence for activation was provided for wild-type and SRKO
BCG peritoneal Mf since both produce high levels of ni-
tric oxide spontaneously when harvested after day 4 of in-
traperitoneal infection (results not shown).
Previous work has demonstrated a role for SR-A in me-
diating cation-independent adhesion of thioglycollate broth–
elicited peritoneal Mf (29) to TCP in the presence of se-
rum (17). To examine whether activated Mf from the
SRKO mouse showed an altered adhesion phenotype in
vitro, BCG-elicited peritoneal cells were harvested and their
adhesion to TCP was examined in the presence of serum
(Fig. 2 A). In the presence of medium (R10) alone or con-
trol antibody (anti–Thy-1), the adhesion of wild-type and
SRKO cells was identical. However, in the presence of
EDTA, which chelates divalent cations, significant adhe-
Figure 1. FACSÒ staining of isolated BCG-activated peritoneal cells.
Peritoneal cells were recruited after intraperitoneal inoculation of 107
CFU of BCG. Cells were harvested and stained with a range of primary
antibodies. a, c, e: wild-type (129) cells. b, d, f: SRKO cells. (a and b) 2F8,
which recognizes the type I and II SR-A; (c and d) FA11, recognizes mac-
rosialin, a macrophage specific marker; (e and f) TIB 120, recognizes
MHC class II antigen. Filled histograms show the indicated surface mark-
ers, and unfilled histograms represent isotype-matched control antibodies.
The results shown are representative of three independent experiments.1434 Macrophage Scavenger Receptor Type A in Endotoxic Shock
sion of the wild-type cells remained, whereas adhesion of
the SRKO cells was completely inhibited. In the additional
presence of the anti–SR-A blocking mAb 2F8, wild-type
adhesion was further reduced to the level of the SRKO
cells.
SR-A mediates endocytosis of a wide range of ligands
(9). The uptake of DiIAcLDL in vitro has provided a rela-
tively convenient assay for this activity (30). The SRKO
mouse now provides us with a model system in which to
investigate both the role of SR-A and the contribution of
other potential scavenger molecules in this uptake. We ob-
served that BCG-activated Mf from the SRKO mouse,
when plated in vitro, endocytosed only 30–40% of the
amount of DiIAcLDL taken up by control cells (Fig. 2 B).
When the 2F8 mAb was added to the medium, the uptake
by the wild-type cells was reduced to the level obtained with
the SRKO cells, whereas addition of an isotype-matched
control mAb (CP) had no effect. Thus the 2F8 mAb can
completely inhibit the component of DiIAcLDL uptake at-
tributable to SR-A. However, this SR-A independent up-
take can be reduced further in the presence of the polyan-
ionic inhibitor Poly G, suggesting the involvement of other
cell surface molecules in the endocytic uptake of modified
lipoproteins (not shown).
Recruitment of Mf to BCG Granulomata. To investigate
whether SR-A is involved in the adhesion and recruitment
of Mf to sites of infection in vivo, wild-type and SRKO
mice were injected intraperitoneally with BCG. In this
model of cellular immunity, Mf are recruited to sites of in-
fection (granulomata) and undergo the process of activation
mediated by IFN-g. Using immunohistochemistry of the
liver, we discovered that SR-A is expressed not only on resi-
dent Kupffer cells and endothelium but also on activated
Mf in granulomata of wild-type mice (Fig. 3). In addition,
staining with F4/80 and FA11 established that, despite lack-
ing SR-A, Mf are efficiently recruited to sites of infection
in vivo (Fig. 3, b and d). These Mf fail to stain with 2F8
since they lack SR-A, but become activated and upregulate
MHC class II (Fig. 3, f and h). Examination of BCG CFU
for up to 2 wk of infection in liver, spleen, and lung showed
that SRKO mice were able to limit mycobacterial replica-
tion (e.g., liver BCG CFU at day 8 of infection: wild-type,
6.20 6 1.23 3 107; SRKO, 6.26 6 3.19 3 107).
Examination of a Role for SR-A in a Model of Endotoxic
Shock. BCG-infected mice contain large numbers of acti-
vated Mf which can produce high levels of proinflamma-
tory cytokines (e.g., TNF-a, IL-1) in response to LPS chal-
lenge (31). Unlike signaling caused by ligation of the CD14
receptor, SR-A is thought to be a neutral receptor for LPS (9).
SRKO mice provide a powerful tool to test whether SR-A
binding to LPS in vivo reduces the risk of endotoxic shock
and were used in the following model of endotoxic shock.
Wild-type and SRKO mice were infected with BCG,
resulting in the production of numerous Mf-rich granulo-
mas in parenchymatous organs. Groups of BCG-infected
mice were challenged with a range of LPS doses by intra-
peritoneal injection at days 12–14 of infection. The signifi-
cant discovery was that the SRKO mice showed approxi-
Figure 2. Functional phenotype of BCG-activated SRKO and wild-
type Mf. (A) Adhesion of activated Mf to FBS-coated TCP. Cells were
plated at 3 3 105 macrophages/well of a 96-well plate in the presence of
various mAbs and/or EDTA. BCG-recruited peritoneal cells from SRKO
and wild-type (129) mice show similar adhesion in medium (R10) alone,
but in the presence of both EDTA and isotype-matched control mAb
(T1), adhesion of SRKO Mf is completely inhibited (compare with
wild-type 129), showing that SR-A accounts for all EDTA-resistant ad-
hesion. Addition of 2F8 mAb and EDTA is required to completely in-
hibit the remaining adhesion of 129 activated Mf. Adhesion is repre-
sented as the percentage of that obtained in medium alone, where 100%
represents an absorbance (OD) at 450 nm of 0.15. Results (mean 6 SD)
are derived from a single experiment (n 5 4) and are representative of
three similar experiments. (B) The uptake of DiIAcLDL by SRKO and
wild-type (129) BCG-recruited peritoneal cells. Cells were harvested as in
A and the uptake of DiIAcLDL measured as described in Materials and
Methods. SRKO endocytose only 40% of the DiIAcLDL taken up by
129 cells. 2F8 mAb reduces the uptake by 129 cells to that of SRKO cells,
whereas an isotype-matched control Ab (CP) has no effect. Uptake of Di-
IAcLDL is expressed by units of fluorescence (mean 6 SD) of four repli-
cate wells and is relative to a blank well of cells without the addition of
DiIAcLDL. Results are derived from a single experiment and are repre-
sentative of at least three similar experiments. Uptake of DiIAcLDL by
129 Mf in the presence of medium or CP is significantly greater than up-
take by SRKO Mf (P ,0.005).1435 Haworth et al.
mately sevenfold higher morbidity and mortality than wild-
type mice (Fig. 4). In preliminary studies, similar results were
obtained when an inactivated preparation of C. parvum was
used to prime the mice before LPS challenge (e.g., LPS
dose 10 mg: mortality of 129, 0%; of SRKO, 75%; n 5 4). In
addition, increased susceptibility to LPS challenge of the
SRKO mice can be demonstrated even in uninfected mice
which have received no stimulus for IFN-g priming of
Mf, although doses of LPS required are two orders of
magnitude higher (e.g., LPS dose 500 mg: mortality of 129,
0%; of SRKO, 66%; n 5 3).
In Vivo Cytokine Production After LPS Challenge. During
the course of serious gram-negative bacterial infections,
LPS induces stimulation of macrophages, which results in
the release of inflammatory mediators (32). The activity of
these mediators, which include prostaglandins and cyto-
kines (e.g., TNF-a, IL-6, and IL-1b) is, in turn, responsi-
ble for hypotension, organ failure, and often death. TNF-a
is produced in large amounts by activated Mf in response
to LPS (33). We reasoned that this molecule was a candi-
date mediator of the difference in mortality observed be-
tween wild-type and SRKO mice. Therefore, we assayed
plasma cytokine levels in BCG infected mice after LPS chal-
lenge. Significantly higher levels of TNF-a were present in
Figure 3. Immunohistochem-
istry of BCG granulomata in
SRKO and wild-type (129)
mice. Livers were collected from
SRKO and wild-type (129) mice
at day 25 of BCG infection and
frozen in OCT embedding me-
dium. Sections of liver were cut
and immunostained with a range
of primary antibodies. a, c, e, and
g: control sections. b, d, f, and h:
SRKO sections. (a and b) F4/80;
resident macrophages (Kupffer
cells) and newly recruited acti-
vated macrophages forming
granulomata are stained. (c and d)
FA11; macrosialin is found in all
macrophages and here shows
the similar morphology of gran-
ulomas in wild-type and SRKO
mice. (e and f) TIB 120; both
129 and SRKO Kupffer cells and
granuloma macrophages express
high levels of MHC class II. (g
and h) 2F8, which recognizes the
type I and II SR-A. (g) Shows
that SR-A is expressed on Kupffer
cells, freshly recruited macro-
phages, and the hepatic endothe-
lium, whereas h shows the absence
of SR-A in the SRKO sections.
Original magnification: 3500.1436 Macrophage Scavenger Receptor Type A in Endotoxic Shock
the plasma of SRKO mice relative to wild-type mice (Fig.
5 A). To confirm that the measured differences in this cy-
tokine were not confounded by differences in response to
viable microorganisms, mice were injected with inactivated
C. parvum and subsequently challenged with LPS. When
serum was assayed 3 h after LPS challenge, levels of TNF-a
were also higher in those samples from mice deficient in
SR-A (Fig. 5 B). In addition, levels of serum IL-6 were as-
sayed at the same time points and similar differences be-
tween the wild-type and SRKO were observed (Fig. 5 C).
In contrast, serum levels of IL-10 showed no significant
difference at these time points (results not shown).
Use of a Blocking mAb to TNF-a. To test whether TNF-a
played a key role in the pathogenesis of endotoxic shock in
this model, we injected SRKO mice with a blocking anti-
body to TNF-a (TN3 19.12) before LPS challenge. In
contrast to mice pretreated with PBS, those receiving TN3
19.12 showed lower and delayed levels of mortality (Table
1). However, this treatment offered only partial protection.
Therefore other proinflammatory cytokines, such as IL-1b,
IL-12, and IL-6, probably also play a role in this mecha-
nism.
Discussion
Our data provide the first direct evidence that SR-A acts
to protect the host against endotoxin. Specifically, we show
that SRKO mice suffer higher mortality in a model of en-
dotoxic shock. After challenge with LPS, serum levels of
proinflammatory cytokines are higher in SRKO relative to
wild-type mice. We establish that TNF-a is an important
mediator in the mechanism of shock in SRKO mice,
through use of a blocking antibody which provides partial
protection.
In addition, we demonstrate, for the first time, that acti-
vated Mf express high levels of SR-A, which is functional
in mediating both cell adhesion and endocytic uptake.
Thus, activated Mf from SRKO mice have an altered ad-
hesion phenotype and express no compensatory mecha-
nism for mediating adhesion in the presence of EDTA. In
contrast, activated Mf from SRKO mice are still able to
mediate uptake of significant amounts of the ligand DiIA-
cLDL. One of the candidate molecules that may account
for this remaining endocytic function is MARCO, a third
class of SR-A, which has previously been shown to medi-
ate binding of DiIAcLDL (34).
The development of granulomata in response to myco-
bacterial infection presents a model system for investigating
molecules involved in cell adhesion and leukocyte recruit-
ment. Recently, cytokines such as TNF-a (35) and IFN-g
Figure 4. Role of SR-A in a model of endotoxic shock. SRKO and
129 mice were injected intraperitoneally with 107 CFU of BCG. At days
12–14 of infection, the mice were injected with various doses of LPS
(mg). The mice were observed for 5 d and mortality was noted. The per-
centage of survival for each dose point represents the mean mortality of a
group of at least five mice. The dose of LPS producing 50% mortality
(LD50; ng/ml) of the 129 mice is: 34.1 6 6.6 (standard error), which is
significantly different from the SRKO LD50: 4.7 6 1.5; P ,0.0001.
Figure 5. Production of TNF-a after LPS challenge of SRKO and wild-type (129) mice. (A and B). SRKO and 129 mice were injected intraperito-
neally with 107 CFU of BCG, or (C) inactivated C. parvum. At 14 d after infection, mice were injected with 10 mg of LPS intraperitoneally. The concen-
tration of (A and C) TNF-a or (B) IL-6 in the serum was determined using capture ELISAs as described in Materials and Methods. Results at each time
point represent the mean concentration 6 SD of a group of five mice. *P ,0.05 compared to SRKO serum cytokine levels.1437 Haworth et al.
(36) have been demonstrated to play a role in the develop-
ment of granulomata. However, studying the key cell sur-
face molecules involved in the adhesion and recruitment of
Mf to granulomata has proved more difficult. For exam-
ple, blockade of the type 3 complement receptor (CR3) pre-
vents formation of Mf-rich granulomata in response to Lis-
teria, but has no effect on the recruitment of Mf to sites of
BCG infection (37). In this laboratory, frozen section assays
have been used to show that SR-A can mediate adhesion
of Mf to tissue ligands (15). Thus, SR-A is a candidate ad-
hesion receptor involved in the Mf recruitment process.
Previous in vivo studies examining this hypothesis have been
frustrated by the short plasma half-life of the 2F8 mAb (our
unpublished results). In the model of BCG infection inves-
tigated here, Mf lacking SR-A were able to migrate to sites
of granuloma formation and become activated. Therefore,
to evaluate any adhesion component attributable to SR-A,
further studies will need to involve the blockade of addi-
tional adhesion receptors on SRKO and wild-type cells.
This model of mycobacterial infection also enabled us to
test the immunocompetence of SRKO mice. Recent work
has suggested that SRKO mice are more susceptible to Lis-
teria monocytogenes and Herpes simplex virus, but the mech-
anism remains unclear (4). However, we found that levels
of mycobacteria within the liver, lung, and spleen of wild-
type and SRKO mice were not significantly different in this
study. This result may reflect that Mf are known to use a
wide  range of receptors to bind mycobacteria, including
CR3 and the mannose receptor (38). Therefore, additional
experiments whereby other cell surface receptors are
blocked on Mf already lacking SR-A are required to deter-
mine if SR-A plays a role in the binding and uptake of my-
cobacteria.
In addition to its potential role in adhesion, SR-A binds
the gram negative cell wall component, LPS, with high af-
finity (39). SR-A is expressed widely by many Mf popu-
ations, such as those in the gut and Kupffer cells in the
liver, and thus is well placed to mediate uptake of LPS in
both physiological and pathological conditions. Results pre-
sented in this paper establish that mice lacking the SR-A
are more susceptible to endotoxic shock. Thus, SR-A plays
a protective role in the uptake and cellular response to LPS.
Furthermore, we demonstrate that SRKO mice produce
more TNF-a and IL-6 in response to LPS challenge than
do wild-type mice. Therefore, to explain why mice defi-
cient in SR-A are more susceptible to endotoxic shock, one
must explore the mechanism that gives rise to higher levels
of proinflammatory cytokines in these mice.
There are at least three possible explanations for these
findings. The first is that there are simply greater numbers
of activated Mf in BCG-infected SRKO compared to wild-
type mice. This could result in increased plasma levels of
TNF-a after LPS challenge simply by summation of se-
creted products from a larger number of Mf. However,
our results indicate that similar numbers of activated Mf
are recruited to the peritoneal cavity in the SRKO and
wild-type mice, and also to sites of granuloma formation
(Fig. 3). Also, the differential response to LPS challenge oc-
curs whether the mice are infected with BCG, injected
with inactivated C. parvum, or left uninfected. Therefore,
differences in numbers of Mf cannot explain these results.
A second explanation is that SRKO and wild-type mice
respond differently to LPS at the single cell level. For ex-
ample, this might result from differences in relative levels of
those receptors which trigger release of cytokines upon LPS
binding, e.g., CD14, and those which bind LPS but are not
thought to trigger a response, e.g., SR-A. Several recep-
tors, such as CD14 and CD11c/CD18, are involved in the
recognition and signaling of events after LPS binding (40,
41). Our unpublished observations indicate no difference in
the level of expression of CD14 on wild type and SRKO
BCG-elicited peritoneal cells. The data support the hy-
pothesis that the response of activated Mf to LPS depends
to some extent on the relative levels of surface expression
of SR-A and CD14. The smaller difference in LPS suscep-
tibility between wild-type and SRKO mice compared with
the extensive resistance of CD14 KO mice may reflect the
fact that other scavenger receptors may also be involved in
this protective role (42).
A third possibility is that SR-A expressed on Mf and
hepatic endothelium clears the LPS more rapidly from the
plasma after challenge. If this theory is correct, then one might
predict a longer plasma half-life of LPS in SRKO mice, re-
sulting in continued stimulation of primed Mf through
CD14, and higher levels of proinflammatory cytokines. Re-
cent studies have reported that in uninfected wild-type and
SRKO mice, there is no detectable difference in the plasma
half-life of LPS (43). However, if the mice are pretreated
with liposomes to eliminate Kupffer cells and other Mf
populations, then the investigators are able to demonstrate
a longer plasma half-life for LPS in the SRKO mice. This
result may indicate that SR-A expressed on hepatic endo-
thelium plays a key role in LPS clearance. In addition, re-
cent work failed to show a difference in the clearance of
Table 1. A Blocking Antibody to TNF-a (TN3 19.12) Provides 
Partial Protection in a Model of Endotoxic Shock
Time after LPS
challenge
Survival
PBS TN3 19.12
h
Expt. 1 12 2/5 5/5
36 1/5 3/5
Expt. 2 12 3/5 5/5
36 0/5 4/5
SRKO mice were injected intraperitoneally with 107 CFU of BCG. At
day 14 of infection, groups of five mice were given either 250 mg of
TN3 19.12 in 200 ml of PBS, or 200 ml of PBS alone. 10 h later mice
were challenged with 25 mg of LPS. Results represent mortality at 12 h
and 36 h after LPS challenge. Results from two independent experi-
ments are shown.1438 Macrophage Scavenger Receptor Type A in Endotoxic Shock
modified LDL (DiIAcLDL) from the circulation of SRKO
relative to wild-type mice (4).
However, there are several important differences from
the BCG infection model described here. Previously we es-
tablished, using in situ hybridization, that the activated Mf
in the granuloma are the main sources of both TNF-a and
IL-1b after LPS challenge (44). Thus, activated Mf in this
model are not only able to secrete cytokines in response to
LPS binding to CD14, but may also bind and mediate up-
take of LPS through SR-A without signaling. This raises
the intriguing possibility of a built-in defense mechanism
whereby, under appropriate circumstances, the activated Mf
may bind and take up LPS through SR-A, and thus reduce
the amount of TNF-a produced from the same cell through
LPS-mediated CD14 signaling. Indeed, this system may be
more complex, since the net result of exposure of an acti-
vated Mf to LPS is likely to depend not only on the rela-
tive expression levels of CD14, SR-A, and other receptors,
but also on interactions between signaling pathways within
the cell. Binding of LPS–LBP complexes to certain domains
of CD14 has been shown to result in activation of c-Jun
NH2-terminal kinase, which results in transcription of genes
encoding for proinflammatory regulators of the immune
response (45). By comparison, the downstream events after
engagement of SR-A with its ligands remain to be estab-
lished.
Further studies are required to determine the relative im-
portance of SR-A in both plasma clearance and in the cel-
lular response to LPS. However, it seems clear that this
work establishes SR-A as an effective protective mecha-
nism in the host response to endotoxin. Our results indicate
that the modulation of SR-A may provide a novel ther-
apeutic approach to control of endotoxic shock in humans.
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